- Home
- ACHC vs SUPN Comparison
ACHC vs SUPN Comparison
Compare ACHC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- SUPN
- Stock Information
- Founded
- ACHC 2005
- SUPN 2005
- Country
- ACHC United States
- SUPN United States
- Employees
- ACHC N/A
- SUPN N/A
- Industry
- ACHC Medical Specialities
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- ACHC Health Care
- SUPN Health Care
- Exchange
- ACHC Nasdaq
- SUPN Nasdaq
- Market Cap
- ACHC 1.7B
- SUPN 2.0B
- IPO Year
- ACHC N/A
- SUPN 2012
- Fundamental
- Price
- ACHC $22.96
- SUPN $45.12
- Analyst Decision
- ACHC Strong Buy
- SUPN Buy
- Analyst Count
- ACHC 10
- SUPN 2
- Target Price
- ACHC $42.85
- SUPN $43.00
- AVG Volume (30 Days)
- ACHC 2.7M
- SUPN 993.2K
- Earning Date
- ACHC 10-29-2025
- SUPN 08-05-2025
- Dividend Yield
- ACHC N/A
- SUPN N/A
- EPS Growth
- ACHC N/A
- SUPN 1411.53
- EPS
- ACHC 1.52
- SUPN 1.14
- Revenue
- ACHC $3,229,609,000.00
- SUPN $665,125,000.00
- Revenue This Year
- ACHC $7.48
- SUPN $4.84
- Revenue Next Year
- ACHC $7.40
- SUPN $17.69
- P/E Ratio
- ACHC $15.08
- SUPN $39.44
- Revenue Growth
- ACHC 5.64
- SUPN 5.55
- 52 Week Low
- ACHC $17.13
- SUPN $29.16
- 52 Week High
- ACHC $82.41
- SUPN $45.60
- Technical
- Relative Strength Index (RSI)
- ACHC 59.28
- SUPN 73.74
- Support Level
- ACHC $21.44
- SUPN $43.77
- Resistance Level
- ACHC $22.35
- SUPN $45.60
- Average True Range (ATR)
- ACHC 0.79
- SUPN 1.20
- MACD
- ACHC 0.30
- SUPN 0.02
- Stochastic Oscillator
- ACHC 91.04
- SUPN 90.59
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.